# NAD+ Research Summary: Mechanism, Precursor Trials and the Evidence Gaps > NAD+ research summary: the redox-and-signaling mechanism, the human precursor trials (NMN, NR) that raise blood NAD+, the infusion data, and what stays unproven. Cited to source. The redox-and-signaling mechanism, the precursor trials that reliably move blood NAD+, the thin infusion data, and the endpoints that remain preliminary. ## Start here This page summarizes the NAD+ research record. The mechanism is settled textbook biochemistry: NAD+ is a redox (electron-shuttling) coenzyme and a fuel for cellular-maintenance enzymes. The human supplement evidence is narrower than the mechanism — controlled trials reliably show oral precursors (NMN, NR) raise blood NAD+, but the leap to disease outcomes is not made. The injectable and infusion data are thinnest of all. Read each finding as what one study measured, with the gaps left visible rather than filled. ## Mechanism: redox carrier and consumed signaling substrate NAD+ does two jobs. As a redox coenzyme it accepts and donates electrons, cycling between NAD+ and NADH to drive glycolysis, the TCA cycle and mitochondrial oxidative phosphorylation — the chain of reactions that makes ATP [5]. As a signaling substrate it is consumed (used up and broken down) by three enzyme families: sirtuins (SIRT1-7), the NAD+-dependent maintenance enzymes that regulate metabolism and DNA repair; PARP1, a DNA-repair enzyme that burns large amounts of NAD+ when DNA is damaged; and CD38, an NAD-consuming surface enzyme that rises with age and inflammation [5]. That consumption is why NAD+ is a renewable but finite pool, and why the salvage pathway matters. The salvage route recycles nicotinamide back into NAD+ through the rate-limiting enzyme NAMPT (nicotinamide phosphoribosyltransferase), whose expression follows a circadian rhythm and rises with exercise [13]. In mouse muscle, knocking down NAMPT lowered NAD+ and impaired respiratory capacity, and the precursor nicotinamide riboside restored both [12] — direct evidence that the salvage pathway is required machinery, not a backup. ## Why NAD+ declines with age Tissue NAD+ falls with age, and the mechanism is partly known. A 2016 mouse study identified CD38 as the principal NAD+-consuming enzyme driving the age-related decline; CD38-knockout mice were protected from NAD+ loss and retained SIRT3-dependent mitochondrial function into old age [2]. In humans, muscle biopsies from 119 older men across three populations tied sarcopenia to a transcriptional signature of mitochondrial dysfunction, fewer mitochondria, and reduced NAD+ biosynthesis and salvage [10]. A foundational 2021 review frames declining NAD+ as a candidate driver of age-related disease across yeast, worm, mouse and human models, with sirtuins, PARPs and CD38 competing for the shrinking pool [5]. ## Nicotinamide riboside (NR): the most clinically studied oral precursor Nicotinamide riboside is the most clinically studied oral NAD+ precursor and the cleanest demonstration that an oral compound can raise NAD+. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, NR at 100, 300 and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively — a clear dose-response — with no flushing, no LDL-cholesterol elevation and no disruption of one-carbon metabolism [4]. A 2026 Phase I crossover study went further, reporting that NR at 1200 mg/day for 8 days raised blood NAD+ by 161% and significantly increased brain NAD+, a 2.3-fold advantage over NMN at the same dose [14]. Biochemically, NR enters via the NRK kinases (NRK1/NRK2), a Preiss-Handler-independent route whose structural basis was mapped in 2007 [15]. ## Nicotinamide mononucleotide (NMN): a direct precursor one step from NAD+ The precursor nicotinamide mononucleotide sits one biochemical step from NAD+ and has the strongest functional human data of the precursors. In prediabetic, postmenopausal women, 10 weeks of NMN at 250 mg/day significantly improved muscle insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp, and remodeled insulin signaling, with no change in body composition or HbA1c [1]. In a multicenter, double-blind RCT in healthy middle-aged adults, NMN at 300, 600 and 900 mg/day for 60 days dose-dependently raised blood NAD+ versus placebo and improved walking distance, with 600 mg/day flagged as optimal and no safety issue at any dose [3]. The unsettled point is regulatory, not pharmacological: the FDA has taken the position that NMN is excluded from the supplement definition because it was investigated as a drug — a status dispute, not a safety ban [5]. ## NAD+ vs NMN vs NR: why precursors are the rational oral route Plain oral NAD+ is poorly taken up intact — the 663-dalton charged molecule does not readily cross into cells whole — so most experts consider precursors the rational oral approach [5]. NMN and NR are absorbed and reliably raise blood NAD+ in randomized trials [4][3], whereas evidence that swallowing intact NAD+ raises cellular NAD+ efficiently is weak. Between the two precursors, a 2026 head-to-head crossover found NR raised blood NAD+ more than NMN at equimolar dose (161% vs 67%) [14], though NMN carries the better-replicated functional endpoint (muscle insulin sensitivity) [1]. The practical upshot the literature supports: if the goal is to raise NAD+, a precursor is the evidence-backed oral route, and plain oral "NAD+" is the weakest oral option. ## NAD+ Infusion: Plasma Clearance and Infusion-Rate Tolerability The intravenous route is documented mainly by its pharmacokinetics, not its outcomes. A pilot study of NAD+ infusion found near-complete plasma removal within roughly the first two hours [5], and reported clinical protocols run ~250-1000 mg per session over hours, slowly, because infusion-rate-dependent flushing and chest or abdominal discomfort appear when the solution is run fast [5]. Controlled efficacy is the gap: the strongest controlled intravenous data are the null NADH Parkinson's results [7], detailed on the [NAD infusion research](/nad-infusion) page. Treat infusion pharmacokinetics as established and infusion efficacy as unproven. ## Tolerability, contamination risk and the regulatory picture NAD+ side effects depend heavily on route. Oral precursors were generally well tolerated in trials — NR showed no adverse-event difference from placebo up to 1000 mg/day [4], and NMN raised no safety signal up to 900 mg/day over 60 days [3]. The route-specific risks sit with injection: infusion-rate-dependent flushing and chest or abdominal discomfort that ease when the rate is slowed [5], plus the documented quality hazard of compounding — an FDA Class I recall of a compounded injectable NAD+ for endotoxin [5]. Two further caveats apply across routes: supplement-grade products vary widely in purity and actual content with no guaranteed third-party testing [5], and a theoretical concern exists that raising NAD+ could support existing cancers, given NAD+'s dual, context-dependent role in oncology [5]. ## Is taking NAD orally effective? Plain oral NAD+ is poorly taken up intact, so most experts consider precursors (NMN, NR) the rational oral route. Oral NMN and NR reliably raise blood NAD+ in randomized trials [4][3], though clinical-endpoint data are mixed [6]. "Effective" depends on the endpoint: effective at raising blood NAD+, unproven for hard clinical outcomes. --- A terrazzo-bright reading of the NAD+ literature — the coenzyme scattered apart from the NMN and NR precursors that rebuild it, the oral trials that moved blood NAD+ set in their own panels from the rapidly-cleared IV drip and the recalled compounded injectable, each claim stamped to its study and each gap left in plain view; no clinic behind the confetti and nothing here infused, injected, dosed, or sold.